Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions
Carotid Artery StenosisStrokes
Interventions
DRUG

Statin

"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"

DRUG

Atorvastatin

"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"

OTHER

Placebo

A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center, New York

07450

Valley Hospital, Ridgewood

12208-3479

Albany Medical College/The Vascular Group at Albany, Albany

14260-7016

State University of New York at Buffalo, Buffalo

10016-6402

New York University School of Medicine, New York

10065-4805

Cornell University Medical College (Weill), New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT02850081 - Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes | Biotech Hunter | Biotech Hunter